Idecabtagene vicleucel not checked
Celgene · bb2121 · BMS-986395
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
- Tested for
- Multiple Myeloma
- Main trialPhase 3
- “The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).”In the company’s words, NCT06045806 on ClinicalTrials.gov
- Other names
- bb2121 · BMS-986395 · ide-cel · Abecma
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 11 Aug 2025 | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | |
| Phase 3Completed | 13 Apr 2026 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | |
| Phase 2Completed | 20 Dec 2023 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma | |
| Phase 2Completed | 15 Jan 2026 | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | |
| Phase 1Completed | 22 Jul 2019 | Study of bb2121 in Multiple Myeloma | |
| Phase 1Completed | 7 Jun 2023 | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | |
| Phase 1Terminated | 25 Apr 2025 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma | |
| Phase 2/3Authorised | not given | LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS | |
| Phase 4Authorised | not given | Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study | |
| Phase 1/2Authorised | not given | A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026